Dermata Therapeutics (DRMAW) to Release Earnings on Wednesday

Dermata Therapeutics (NASDAQ:DRMAW) is projected to announce its results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter.

Dermata Therapeutics Stock Down 1.7%

Shares of DRMAW stock opened at $0.02 on Tuesday. The stock has a fifty day moving average price of $0.02 and a 200 day moving average price of $0.02. Dermata Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.04.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.

The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.